Results 11 to 20 of about 1,927 (159)
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir [PDF]
Antimicrobial Agents and Chemotherapy, 2011 ABSTRACT The identification of transporters of the HIV integrase inhibitor raltegravir could be a factor in an understanding of the pharmacokinetic-pharmacodynamic relationship and reported drug interactions of raltegravir.
Andrew Owen +7 more
openaire +2 more sources
Acta Médica Portuguesa, 2022 Introduction: Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy.
Rosário Serrão +15 more
doaj +1 more source
Raltegravir Pharmacokinetics During Pregnancy [PDF]
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014 We evaluated the pharmacokinetics (PK) of raltegravir in HIV-infected women during pregnancy and postpartum.International Maternal Pediatric Adolescent AIDS Clinical Trials 1026s is an ongoing prospective study of antiretroviral PK during pregnancy (NCT00042289).
Watts, D Heather +13 more
openaire +5 more sources
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. [PDF]
PLoS ONE, 2014 The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed.
Jonathan Z Li +30 more
doaj +1 more source
Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. [PDF]
PLoS ONE, 2016 BACKGROUND:Irinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods.
Lawrence Soon-U Lee +13 more
doaj +1 more source
Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]
PLoS ONE, 2012 Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith +10 more
doaj +1 more source
Cells, 2022 Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study
Gaurav Kumar +5 more
doaj +1 more source
HIV resistance to raltegravir [PDF]
European Journal of Medical Research, 2009 Similar to all antiretroviral drugs, failure of raltegravir-based treatment regimens to fully supress HIV replication almost invariably results in emergence of HIV resistance to this new drug. HIV resistance to raltegravir is the consequence of mutations located close to the integrase active site, which can be divided into three main evolutionary ...
openaire +6 more sources
Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites [PDF]
International Journal on Bioinformatics & Biosciences, vol. 2, pp.
21-29, 2012, 2012 HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell.
arxiv +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2019 Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite
Jos Lommerse +10 more
doaj +1 more source